Post-operative colic pain in horses: firocoxib vs flunixin meglumine — POSSIBLE

In horses recovering from colic surgery, does firocoxib provide analgesia comparable to flunixin meglumine with fewer gastrointestinal or renal adverse effects?

Shelf #200 · gate-verified and displayed under the developer's blinded-trial rule

POSSIBLE: The one clinical trial on this shelf — a multicentre, blinded, randomised trial in 56 horses recovering from surgery for small intestinal strangulating obstruction — found no significant difference in pain scores between firocoxib and flunixin meglumine (P = 0.2), while a validated biomarker of endotoxaemia (plasma soluble CD14) rose more often with flunixin meglumine (3.23-fold relative increased risk, P = 0.04; absolute rates are not given in the record). An earlier experimental study of ischemic-injured jejunum (18 horses) points the same way on the gut: pain scores did not significantly increase after surgery with either drug, but flunixin meglumine retarded mucosal recovery while firocoxib did not, and an ex vivo study in horses undergoing elective surgery confirmed firocoxib's COX-1-sparing profile. What no carded record shows is a direct comparison of clinical gastrointestinal or renal adverse events after colic surgery — the safety advantage rests on a biomarker and on mucosal-recovery endpoints, not on counted adverse events — and the pain comparison comes from a superiority-designed trial, not a formal noninferiority trial, so 'comparable analgesia' means 'no difference detected in 56 horses', not proven equivalence. Drafted Nov 10, 2026 (VetMed build, topic #200); all figures from abstracts fetched and verified at drafting.

Ziegler 2019: in 56 post-surgical SISO horses, pain scores did not differ between firocoxib and flunixin meglumine (P = 0.2), but an endotoxaemia biomarker rose more with flunixin

Multicentre, blinded, randomised clinical trial (record's own study-design wording)

Who: Horses: 56 horses with small intestinal strangulating obstruction (SISO) treated surgically at three university hospitals from 2015 to 2017, given post-operatively either flunixin meglumine (1.1 mg/kg, i.v., q12h) or firocoxib (0.3 mg/kg, i.v. loading dose; 0.1 mg/kg, i.v., q24h), with clinical monitoring and plasma sampling before surgery and at 12, 24 and 48 hours post-operatively.

Result: COX-2 selectivity was confirmed by a relative lack of inhibition of the COX-1 prostanoid thromboxane B2 by firocoxib and significant inhibition by flunixin meglumine (P = 0.014); both drugs inhibited the COX-2 prostanoid prostaglandin E2. There were no significant differences in pain scores between groups (P = 0.2). There was a 3.23-fold increased relative risk (P = 0.04) of increased plasma soluble CD14 — a validated biomarker of equine endotoxaemia — in horses treated with flunixin meglumine; the record gives no absolute rates for this outcome.

Watch out: All horses had been treated with flunixin meglumine before referral, and many were also treated with lidocaine, which the authors note has been shown to mitigate the deleterious effects of flunixin meglumine. The trial was designed to test superiority on endotoxaemia signs, not formal noninferiority of analgesia, and it reports no counted gastrointestinal or renal adverse events — the gut-safety signal is a biomarker (soluble CD14), not clinical adverse events.

Ziegler AL, Freeman CK, Fogle CA, Burke MJ, Davis JL, Cook VL, Southwood LL, Blikslager AT. Multicentre, blinded, randomised clinical trial comparing the use of flunixin meglumine with firocoxib in horses with small intestinal strangulating obstruction. Equine Vet J. 2019;51(3):329-335. PMID: 30156312. Registry ID: none in the record. MeSH: 4-Butyrolactone/administration & dosage,analogs & derivatives,therapeutic use · Animals · Anti-Inflammatory Agents, Non-Steroidal/administration & dosage,therapeutic use · Clonixin/administration & dosage,analogs & derivatives,therapeutic use · Female · Horse Diseases/drug therapy · Horses · Intestinal Obstruction/complications,veterinary · Male · Postoperative Pain/drug therapy,veterinary · Random Allocation · Sulfones/administration & dosage,therapeutic use

Cook 2009: in ischemic-injured equine jejunum, both drugs controlled pain scores, but flunixin meglumine retarded mucosal recovery and firocoxib did not

Comparative study (record's own publication types; randomisation and blinding not stated)

Who: Horses: 18 horses in an experimental setting, 6 per group, receiving saline (0.9% NaCl) solution (1 mL/50 kg, IV), flunixin meglumine (1.1 mg/kg, IV, q 12 h), or firocoxib (0.09 mg/kg, IV, q 24 h) before 2 hours of jejunal ischemia, monitored via pain scores with butorphanol available for analgesia, and assessed after 18 hours.

Result: Pain scores did not significantly increase after surgery in horses receiving flunixin meglumine or firocoxib. Transepithelial resistance of ischemic-injured jejunum from horses treated with flunixin meglumine was significantly lower than in saline- or firocoxib-treated horses, and lipopolysaccharide permeability across ischemic-injured mucosa was significantly increased in horses treated with flunixin meglumine. Treatment did not affect epithelial restitution. The authors concluded that flunixin meglumine retarded mucosal recovery in ischemic-injured jejunum whereas firocoxib did not, that both were effective visceral analgesics, and that firocoxib may be advantageous in horses recovering from ischemic intestinal injury.

Watch out: This is the Cook programme's experimental study the draft anchor pointed to — but it is an experimental ischemia model in 18 horses, not horses recovering from clinical colic surgery, and the record does not state randomisation or blinding, so neither is claimed. Pain was scored while butorphanol rescue was available, which can compress between-drug pain differences.

Cook VL, Meyer CT, Campbell NB, Blikslager AT. Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum. Am J Vet Res. 2009;70(8):992-1000. PMID: 19645580. Registry ID: none in the record. MeSH: 4-Butyrolactone/analogs & derivatives,therapeutic use · Analysis of Variance · Animals · Anti-Inflammatory Agents, Non-Steroidal/therapeutic use · Blotting, Western/veterinary · Clonixin/analogs & derivatives,therapeutic use · Cyclooxygenase 1/metabolism · Cyclooxygenase 2/metabolism · Eicosanoids/blood · Electrophoresis, Polyacrylamide Gel/veterinary · Horse Diseases/drug therapy · Horses · Ischemia/drug therapy,veterinary · Jejunal Diseases/drug therapy,veterinary · Sulfones/therapeutic use · Thromboxane B2/blood

Duz 2015: ex vivo, firocoxib spared COX-1 activity after elective surgery while flunixin meglumine reduced it — the mechanism behind the gut-safety claim

Comparative ex vivo study (randomisation and blinding not stated in the record)

Who: Horses: 4 healthy horses for in vitro experiments and 12 healthy horses (6 males and 6 females; 5 Thoroughbreds, 5 Warmbloods, and 2 ponies) undergoing elective surgery for ex vivo experiments; the 12 surgical horses received flunixin meglumine (1.1 mg/kg, IV, q 12 h) or firocoxib (0.09 mg/kg, IV, q 24 h), with blood sampled before and 2 and 24 hours after administration.

Result: At 2 and 24 hours after NSAID administration, COX-1 activity was reduced, compared with baseline activity, for the flunixin meglumine group only, and relative COX-1 activity was significantly greater for the firocoxib group compared with the flunixin meglumine group. There was no significant change in COX-2 activity after surgery for either group. The authors concluded that, compared with flunixin meglumine, firocoxib had COX-1-sparing effects ex vivo in equine patients that underwent elective surgery.

Watch out: Supporting mechanism only: these were healthy horses undergoing elective surgery, not colic cases, and the endpoints are ex vivo prostanoid measures, not pain scores or adverse events. Agreement between the in vitro and ex vivo measurement of COX-1 activity was poor on Bland-Altman analysis, per the record itself.

Duz M, Parkin TD, Cullander RM, Marshall JF. Effect of flunixin meglumine and firocoxib on ex vivo cyclooxygenase activity in horses undergoing elective surgery. Am J Vet Res. 2015;76(3):208-15. PMID: 25710756. Registry ID: none in the record. MeSH: 4-Butyrolactone/administration & dosage,analogs & derivatives,pharmacology · Animals · Anti-Inflammatory Agents, Non-Steroidal/administration & dosage,pharmacology · Clonixin/administration & dosage,analogs & derivatives,pharmacology · Cyclooxygenase 1/drug effects · Cyclooxygenase 2/drug effects · Elective Surgical Procedures/veterinary · Female · Horses/blood,surgery · Male · Sulfones/administration & dosage,pharmacology

Synthesis: pain control looked the same in the one blinded clinical trial; the gut advantage is real on biomarkers and mucosal recovery, unproven on counted adverse events

Synthesis

Who: Synthesis of the cards above: Ziegler 2019 (56 post-surgical SISO horses, multicentre blinded randomised trial), Cook 2009 (18 horses, experimental jejunal ischemia) and Duz 2015 (12 healthy horses undergoing elective surgery, ex vivo COX activity).

Result: On analgesia, the evidence is concordant but thin: no significant pain-score difference between firocoxib and flunixin meglumine in the blinded clinical trial (P = 0.2), and pain scores did not significantly increase after surgery with either drug in the experimental study. On the gut, three different endpoints point the same way — soluble CD14 (endotoxaemia biomarker) rose more with flunixin meglumine (3.23-fold relative increased risk, P = 0.04), flunixin meglumine retarded recovery of ischemic-injured jejunum while firocoxib did not, and firocoxib spared COX-1 activity ex vivo. On renal effects and on clinical gastrointestinal adverse events after colic surgery, no carded record reports a head-to-head comparison at all.

Watch out: Anchor correction versus the draft: the draft anchor expected a randomised COX-2-vs-nonselective programme from Cook and successors — that programme is genuine, but its clinical randomised trial is Ziegler 2019 (Cook is a co-author), and Cook 2009 itself is a small experimental ischemia study whose record states neither randomisation nor blinding. No carded record compares clinical GI or renal adverse-event rates, so this shelf cannot stamp the 'fewer adverse effects' half of its question above POSSIBLE.

Synthesis of Ziegler AL et al. PMID: 30156312; Cook VL et al. PMID: 19645580; Duz M et al. PMID: 25710756. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.